IBI-302 is a Fusion Protein owned by Innovent Biologics, and is involved in 6 clinical trials, of which 2 were completed, 3 are ongoing, and 1 is planned.
IBI-302 is a bi-specific fusion protein that inhibits the activation of complement pathway(C3b and C4b) and the expression of vascular endothelial growth factor (VEGF) , inflammation-related molecules including TNF-alpha, CCL-2. This leads to inhibition of the infiltration of macrophages and neutrophils and the deposition of membrane-attack-complex.
The revenue for IBI-302 is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the IBI-302 NPV Report.
IBI-302 is originated and owned by Innovent Biologics.
IBI-302 is under development for the treatment of wet age-related macular degeneration, retinal fibrosis, macular atrophy and diabetic macular edema. It is a bi-specific fusion protein that targets VEGF expression and complement factor (C3b and C4b). It was also under development for metabolic diseases and solid tumors. It is administered through intravitreal and intraocular route.
Innovent Biologics Overview
Innovent Biologics is a biopharmaceutical company that focuses on the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112, IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311
The company reported revenues of (Renminbi) CNY4,269.7 million for the fiscal year ended December 2021 (FY2021), an increase of 11.1% over FY2020. The operating loss of the company was CNY2,988.6 million in FY2021, compared to an operating loss of CNY790.4 million in FY2020. The net loss of the company was CNY3,138.1 million in FY2021, compared to a net loss of CNY998.4 million in FY2020.
Quick View – IBI-302
|Highest Development Stage|